Ageing and Cancer
Research & Treatment
https://doi.org/10.37155/2972-4759-2023-01-01-4

Supplementary information

Protocol for a pilot trial to implement diagnostics for clonal hematopoiesis of indeterminate potential into routine clinical care of older patients with breast cancer

Nina Rosa Neuendorff, Ann-Kathrin Bittner, Sarah Flossdorf, Tessy Mauer, Florian Schmitz, Nils von Neuhoff, Johannes Köster, Felix Mölder, Markus Schneider, Amin T. Turki, Rainer Kimmig, Hans Christian Reinhardt, Oliver Hoffmann, Bastian von Tresckow

Table S1. Questionnaire on patient satisfaction and potential fears.

		I totally agree	*I agree*	*I neither agree nor disagree*	*I don't agree*	*I strongly disagree*
Questions on satisfaction with the study						
1)	I was happy to take part in the study.					
2)	It gives me a very good feeling personally, that I was able to contribute to the research about my illness.					
3)	I think that the participation in this study has an additional value on my health.					
4)	Dealing with my illness was an emotionally draining task.					
Questions on study organization, comprehension and quality of informed consent						
5)	The process and the explanation of the study was clear and comprehensible.					
6)	I basically understood why individual study parts were realized.					
7)	I was satisfied with the information about the CHIP -diagnostic.					
Questions on patient education						
8)*	The CHIP-Positivity was intelligibly explained to me.					
9)*	The information letter concerning CHIP helped me to have the most important information at hand again after the medical consultation.					
10)*	I think it's reasonable that my primary care physician received information about my CHIP-Positivity.					
Questions on potential fears						
11)*	The presence of CHIP worries me a lot.					
12)*	Knowing I'm CHIP-positive stresses me out.					
13)*	I wish I didn't know that I'm CHIP-positive.					

*Questions 8-13 are only provided to patients who are tested as CHIP positive.

Table S2. Genes included in targeted sequencing (myeloid panel).

ABL1
ANKRD26
ARID1A
ASXL1
ASXL2
ATM
ATRX
BCOR
BCORL1
BRAF
BRCC3
CALR
CBL
CBLB
CBLC
CCND2
CDKN2A
CEBPA
CHEK2
CREBBP
CSF3R
CSMD1
CSNK1A1
CTCF
CUX1
CXCR4
DDX41
DHX15
DNMT3A
EED
ELANE
ETNK1
ETV6
EZH2
FANCA
FANCL
FLT
GATA1
GATA2
GNAS
GNB1
HNRNPK
HRAS
IDH1
IDH2
IKZF1
JAK1
JAK2
KAK3
KDM6A
KIT
KMT2A
KMT2D
KRAS
LUC7L2
MECOM
MET
MPL
MYC
NF1
NOTCH1
NOTCH2
NPM1
NRAS
NSD1
NUP214
PAX5
PDGFRA
PHF6
PIGA
PML
PPM1D
PRPF40B
PTEN
RAD21
RAF1
RB1
RBBP6
RPS19
RTEL1
RUNX1
SAMD9
SAMD9L
SBDS
SETBP1
SETD2
SF1
SF3A1
SF3B1
SH2B3
SMC1A
SMC3
SOS1
SRP72
SRSF2
STAG1
STAG2
STAT3
STAT5B
SUZ12
TERC
TERT
TET2
THPO
TP53
U2AF1
U2AF2
WT1
ZBTP7A
ZRSR2

Genes in bold are included as required in WHO classification of myeloid malignancies.

Table S3. Size of confidence intervals in relation to number of approached versus participating patients.

N p	50	100	150	200	250	300
0.5	0.289	0.203	0.165	0.143	0.127	0.116
0.6	0.284	0.199	0.162	0.14	0.125	0.114
0.7	0.267	0.187	0.152	0.131	0.117	0.107
0.8	0.237	0.165	0.134	0.115	0.103	0.094
0.9	0.185	0.127	0.103	0.088	0.078	0.071

N: number of approached patients; p: real participation rate.